TY - JOUR
T1 - Contributions of the Japanese Gynecologic Oncology Group (JGOG) in Improving the Quality of Life in Women With Gynecological Malignancies
AU - Futagami, Masayuki
AU - Yokoyama, Yoshihito
AU - Shimada, Muneaki
AU - Sato, Shinya
AU - Miyagi, Etsuko
AU - Tozawa-Ono, Akiko
AU - Suzuki, Nao
AU - Fujimura, Masaki
AU - Aoki, Yoichi
AU - Sagae, Satoru
AU - Sugiyama, Toru
N1 - Publisher Copyright:
© 2017, Springer Science+Business Media New York.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - The Japanese Gynecologic Oncology Group (JGOG) is leading Japan in the treatment of gynecological malignancies. The JGOG consists of three treatment committees focusing on uterine cervical cancer, endometrial cancer, and ovarian cancer. Each committee makes efforts to improve treatment and diagnosis. In addition, the Supportive and Palliative Care Committee was established in 2015. Novel studies of supportive care and palliative care have been initiated by this committee. Furthermore, surveys about not only treatment results such as overall survival rates but also quality of life (QOL) and cost-effectiveness assessments are performed by the ovarian cancer committee. Improvements of patients’ QOL in the treatment of gynecological malignancies were divided into three concepts as follows: QOL associated with cancer treatment, health care after cancer therapy, and progression of cancer. In this review, we report the contributions and future plans for the improvement of QOL in patients with gynecological malignancies.
AB - The Japanese Gynecologic Oncology Group (JGOG) is leading Japan in the treatment of gynecological malignancies. The JGOG consists of three treatment committees focusing on uterine cervical cancer, endometrial cancer, and ovarian cancer. Each committee makes efforts to improve treatment and diagnosis. In addition, the Supportive and Palliative Care Committee was established in 2015. Novel studies of supportive care and palliative care have been initiated by this committee. Furthermore, surveys about not only treatment results such as overall survival rates but also quality of life (QOL) and cost-effectiveness assessments are performed by the ovarian cancer committee. Improvements of patients’ QOL in the treatment of gynecological malignancies were divided into three concepts as follows: QOL associated with cancer treatment, health care after cancer therapy, and progression of cancer. In this review, we report the contributions and future plans for the improvement of QOL in patients with gynecological malignancies.
KW - Gynecological malignancies
KW - JGOG
KW - QOL
KW - Supportive and Palliative Care Committee
UR - http://www.scopus.com/inward/record.url?scp=85015745976&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015745976&partnerID=8YFLogxK
U2 - 10.1007/s11912-017-0580-y
DO - 10.1007/s11912-017-0580-y
M3 - Review article
C2 - 28303492
AN - SCOPUS:85015745976
VL - 19
JO - Current Oncology Reports
JF - Current Oncology Reports
SN - 1523-3790
IS - 4
M1 - 25
ER -
